Pfiz­er nabs col­orec­tal can­cer OK for Braftovi; Bris­tol My­ers, Pfiz­er pull out of re­gion­al deal with Por­to­la

→ Ten months af­ter Ar­ray showed off the pos­i­tive BEA­CON-CRC da­ta that en­ticed Pfiz­er to write a $11.4 bil­lion buy­out check, the phar­ma gi­ant has of­fi­cial­ly bagged the OK. Braftovi is now ap­proved (in com­bi­na­tion with Er­bitux, or ce­tux­imab) to treat BRAF V600E-mu­tant metasta­t­ic col­orec­tal can­cer. An es­ti­mat­ed 15% of all pa­tients with metasta­t­ic col­orec­tal can­cer har­bor BRAF mu­ta­tions, which rep­re­sent a poor prog­no­sis. In a Phase III tri­al, the tar­get­ed ther­a­py in­duced a me­di­an OS of 8.4 months ver­sus 5.4 months for con­trol (p=0.0003).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER